| A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Active, not recruiting | Phase 2 | 2026-09-28 | | NCT05490446 |
|---|
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients | splenic marginal zone lymphoma | Active, not recruiting | Phase 3 | 2026-07-22 | | NCT05735834 |
|---|
| ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable) | metastatic prostate carcinoma | Recruiting | Phase 3 | 2026-04-28 | | NCT04916613 |
|---|
| Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma | Transformed Splenic Marginal Zone Lymphoma | Recruiting | Not stated | 2026-01-16 | | NCT06712459 |
|---|
| Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. | cardiovascular disorder, vascular disorder, vasculitis | Recruiting | Not applicable | 2025-09-15 | | NCT03290456 |
|---|